Takeda Pharmaceutical Co Ltd
TAK NYSE· Pharmaceutical Preparations
Last close · Oct 30, 2026
$20.91
KIRA · Stoqly’s AI analyst, in plain words
- Takeda Pharmaceutical Co Ltd had $29.9B of revenue in fiscal 2026, down 0.5% on the year before. Over five years, revenue changed −0.2% a year on average.
- Its operating margin was 0.1%, down 7.3 pts: of every 100 in sales, about 0 is left after running the business.
- Takeda Pharmaceutical Co Ltd lost $1.0B in fiscal 2026.
- Free cash flow was $5.7B in fiscal 2026, 19.2% of revenue.
- Takeda Pharmaceutical Co Ltd returned $2.4B to shareholders in fiscal 2026, 42% of free cash flow. The diluted share count fell 1.9%.
- Takeda Pharmaceutical Co Ltd owes $26.9B more than it holds in cash, about 5.6 years of operating profit.
Market cap
$65.9B
P/E
—
Revenue
$29.9B
Net income
−$1.0B
Free cash flow
$5.7B
Operating margin
0.1%
Takeda Pharmaceutical Co Ltd in 30 seconds · fiscal 2026
Are sales growing?
−0.5%
No. Sales fell 0.5% last year.
Does it make a profit?
−3.4%
No. It lost money last year.
Does profit turn into cash?
19.2%
Yes. 19.2% of sales ends up as free cash.
Is debt under control?
5.6x
Heavy. Repaying its debt would take 5.6 years of operating profit.
How healthy are the accounts?
5 / 9
Mixed. It passes 5 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Takeda Pharmaceutical Co Ltd does
No business description yet.
- Fiscal year ends
- March 31, 2026
- Latest annual report
- 20-F · Jun 17, 2026
- Legal name
- TAKEDA PHARMACEUTICAL CO LTD
- CIK
- 0001395064
Takeda Pharmaceutical Co Ltd · TAK · stoqly.net
Results and finances
The last 5 fiscal years. Amounts in USD. Compiled by stoqly.net.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $31.8B | $29.7B | $29.5B | $30.1B | $29.9B |
| Revenue growth | 5.3% | −6.4% | −0.8% | 1.9% | −0.5% |
| Gross margin | 69.0% | 69.1% | 66.5% | 65.5% | 65.1% |
| Operating margin | 12.9% | 12.2% | 5.0% | 7.5% | 0.1% |
| Net income | $2.0B | $2.3B | $997M | $708M | −$1.0B |
| Net margin | 6.4% | 7.9% | 3.4% | 2.4% | −3.4% |
| Diluted EPS | $0.65 | $0.75 | $0.32 | $0.22 | −$0.32 |
| Cash | |||||
| Cash from operations | $10.0B | $7.2B | $5.0B | $6.9B | $6.9B |
| Capital expenditure | $1.1B | $1.0B | $1.2B | $1.3B | $1.2B |
| Free cash flow | $8.9B | $6.2B | $3.7B | $5.6B | $5.7B |
| FCF margin | 28.0% | 20.8% | 12.7% | 18.7% | 19.2% |
| Dividends paid | $2.5B | $2.1B | $2.0B | $2.0B | $2.1B |
| Share buybacks | $690M | $199M | $16.1M | $340M | $342M |
| Share count change | 0.2% | −0.5% | 0.7% | 1.6% | −1.9% |
| Debt and strength | |||||
| Cash and short-term investments | $7.0B | $4.0B | $3.0B | $2.6B | $3.7B |
| Debt incl. finance leases | $35.7B | $32.9B | $32.0B | $30.2B | $30.6B |
| Shareholders' equity | $46.7B | $47.7B | $48.1B | $46.4B | $46.6B |
| Net debt / EBITDA | 3.1x | 3.4x | 4.5x | 3.8x | 5.6x |
| Current ratio | 1.2x | 1.0x | 1.1x | 1.0x | 1.1x |
| Interest coverage | 3.8x | 4.2x | 1.8x | 2.5x | 0.0x |
| Returns and quality | |||||
| Return on capital | 4.1% | 4.0% | 1.9% | 2.0% | 0.0% |
| Return on equity | 4.4% | 5.0% | 2.1% | 1.5% | −2.2% |
| Piotroski F-score | 6 | 7 | 5 | 5 | 5 |
| Altman Z'' | 1.6 | 1.4 | 1.5 | 1.4 | 1.2 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$13.1M
13 insiders
Of sales under plans
19%
$2.5M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Takeda Pharmaceutical Co Ltd · TAK · stoqly.net
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $20.91 a share, the company is worth $65.9B.
Compiled and analysed by stoqly.net from SEC EDGAR XBRL filings (CIK 0001395064). Latest version: stoqly.net/companies/tak. Data updated November 1, 2026. Filed in JPY under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only — not investment advice. Check the original filings before relying on any figure.